Amgen's cholesterol-lowering drug Repatha was approved in 2015. "Amgen Sees Positive Results in Repatha Study," at 4:23 p.m ET and a subsequent update incorrectly stated when the drug was approved in the fourth paragraph.

(END) Dow Jones Newswires

February 02, 2017 19:05 ET (00:05 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Amgen Charts.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Amgen Charts.